{"entity":{"id":"nct06813079","kind":"trial","name":"Using Tumor Models to Determine Treatments","aka":[],"tldr":"A phase 2 trial of cobimetinib, ponatinib, brigatinib, selinexor and other drugs in pancreatic cancer, run by University Health Network, Toronto, now recruiting.","summary":"Using Tumor Models to Determine Treatments is a phase 2, interventional study registered as NCT06813079 by University Health Network, Toronto, with a registry enrolment figure of 25 participants, started 2025-04-07 and due to reach its primary completion in 2028-02-17. Interventions recorded: Cobimetinib; Ponatinib; Brigatinib; Colchicine; Selinexor; Abemaciclib; Neratinib; Doxorubicin; Etoposide; Ceritinib. Conditions listed: Pancreatic Ductal Carcinoma; Advanced Cancer; Epithelial Tumor. Primary outcome: Objective response rate (ORR). Pancreatic eligibility wording from the registry: \"Advanced inoperable malignant epithelial pancreatic ductal carcinomas (i\". Sites: Canada. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06813079","url":"https://clinicaltrials.gov/study/NCT06813079"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["cobimetinib","ponatinib","brigatinib","selinexor","abemaciclib","neratinib","doxorubicin","etoposide","ceritinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06813079","phase":"2","setting":"ADOPT: Adaptive Organoid-Based Precision Therapy Study in Pancreatic Cancer - A Prospective Single-Arm Phase II Trial","sponsor":"University Health Network, Toronto","enrolled":25,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06813079/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/"},{"id":"brigatinib","kind":"drug","name":"Brigatinib","route":"/drugs/brigatinib/"},{"id":"ceritinib","kind":"drug","name":"Ceritinib","route":"/drugs/ceritinib/"},{"id":"cobimetinib","kind":"drug","name":"Cobimetinib","route":"/drugs/cobimetinib/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"},{"id":"neratinib","kind":"drug","name":"Neratinib","route":"/drugs/neratinib/"},{"id":"ponatinib","kind":"drug","name":"Ponatinib","route":"/drugs/ponatinib/"},{"id":"selinexor","kind":"drug","name":"Selinexor","route":"/drugs/selinexor/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}